TRCT
ALLO icon

Tower Research Capital (TRC)’s Allogene Therapeutics ALLO Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.3K Sell
11,698
-18,605
-61% -$40.9K ﹤0.01% 3378
2026
Q1 		$73.9K Buy
30,303
+21,688
+252% +$43.5K ﹤0.01% 2421
2025
Q4 		$11.8K Sell
8,615
-2,440
-22% -$3.22K ﹤0.01% 3549
2025
Q3 		$13.7K Sell
11,055
-6,539
-37% -$7.8K ﹤0.01% 3659
2025
Q2 		$19.9K Buy
17,594
+8,276
+89% +$11K ﹤0.01% 3683
2025
Q1 		$13.6K Sell
9,318
-20
-0.2% -$38 ﹤0.01% 3343
2024
Q4 		$19.9K Buy
9,338
+3,963
+74% +$9.77K ﹤0.01% 3186
2024
Q3 		$15.1K Sell
5,375
-26,210
-83% -$69.9K ﹤0.01% 3424
2024
Q2 		$73.6K Buy
31,585
+25,513
+420% +$75.3K ﹤0.01% 2811
2024
Q1 		$27.1K Sell
6,072
-51,725
-89% -$216K ﹤0.01% 2732
2023
Q4 		$186K Buy
57,797
+49,548
+601% +$141K ﹤0.01% 2170
2023
Q3 		$26.1K Sell
8,249
-5,385
-39% -$23.6K ﹤0.01% 3137
2023
Q2 		$67.8K Buy
13,634
+5,200
+62% +$28.1K ﹤0.01% 2331
2023
Q1 		$42K Sell
8,434
-8,020
-49% -$51.4K ﹤0.01% 2650
2022
Q4 		$104K Sell
16,454
-10,824
-40% -$100K ﹤0.01% 1804
2022
Q3 		$295K Buy
27,278
+8,851
+48% +$120K ﹤0.01% 1562
2022
Q2 		$210K Sell
18,427
-8,238
-31% -$73.1K ﹤0.01% 1739
2022
Q1 		$243K Buy
26,665
+11,859
+80% +$124K ﹤0.01% 1592
2021
Q4 		$221K Buy
14,806
+2,499
+20% +$44.1K ﹤0.01% 1690
2021
Q3 		$316K Buy
12,307
+6,077
+98% +$144K 0.01% 1349
2021
Q2 		$162K Buy
6,230
+1,065
+21% +$30.4K ﹤0.01% 2076
2021
Q1 		$182K Sell
5,165
-107
-2% -$3.61K ﹤0.01% 2092
2020
Q4 		$133K Buy
5,272
+1,833
+53% +$59.7K ﹤0.01% 2085
2020
Q3 		$130K Sell
3,439
-9,544
-74% -$360K ﹤0.01% 2926
2020
Q2 		$556K Buy
12,983
+12,919
+20,186% +$467K 0.02% 925
2020
Q1 		$1K Sell
64
-4,152
-98% -$98.9K ﹤0.01% 2719
2019
Q4 		$110K Buy
4,216
+1,338
+46% +$36.9K 0.01% 879
2019
Q3 		$78K Buy
2,878
+2,804
+3,789% +$79.9K 0.01% 1498
2019
Q2 		$2K Buy
+74
New +$2.06K ﹤0.01% 3226

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Tower Research Capital (TRC)'s ALLO Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Allogene Therapeutics (ALLO) stake by 61% in Q2 2026, selling an estimated $40.9K and leaving 11,698 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3378.

Tower Research Capital (TRC) first reported a position in ALLO in Q2 2019 and has held it in 29 quarters since. The position peaked at $556K in Q2 2020. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Tower Research Capital (TRC) held 11,698 shares of Allogene Therapeutics worth $24.3K as of Q2 2026.
  • Tower Research Capital (TRC) sold 18,605 Allogene Therapeutics shares in Q2 2026, an estimated $40.9K.
  • Allogene Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3378 holding.
  • Tower Research Capital (TRC) first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Allogene Therapeutics position peaked at $556K in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.